Financial Daily from THE HINDU group of publications
Wednesday, May 11, 2005

News
Features
Stocks
Port Info
Archives
Google

Group Sites

Corporate - Alliances & Joint Ventures


Natco tie-up with US varsity

Our Bureau

HYDERABAD: Natco Pharma Ltd has announced a tie-up with the US-based Temple University.

In a press release here on Tuesday, the company said the tie-up facilitates undertaking of specified biological studies by the university, for establishing the in vivo efficacy of some promising anti-cancer compounds useful in the treatment of chronic myeloid leukaemia (CML).

The company said it had, as a part of its research activities, identified, designed and synthesised, at its Research Centre (Natco Research Centre), certain potentially active anti-cancer compounds useful in the treatment of CML. It has already completed the in vitro studies of these compounds and found them been highly satisfactory.

Natco Pharma, with the active assistance of Temple University, seeks to complete the in vivo studies to establish the positive efficacy of the compounds by the end 2005.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page


Stories in this Section
Mishap at Premier Explosives


GAIL in talks to buy Indonesian LNG for Dabhol
Amrit Foods to double production capacity of flavoured milk
New Reva to be launched today
Godrej board nod for share buyback
Jubilant to raise $75 m
Kribhco bags NPC award
Birlas move HC seeking intervention
Ecoboard back in black
Malladi Drugs acquires US-based Novus
Bajaj Electricals in pact with US co
Dai Ichi in pact with GVK Bio
Natco tie-up with US varsity
`Family businesses should professionalise management'
LML plans 100 cc bike launch in August
Reliance to maintain export volumes of diesel, petrol at present levels
Maruti's Swift likely to be priced in Rs 4.5 lakh-6.5 lakh range


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line